In addition to GLP-1R-mediated effects on ICP itself, the weight loss associated with prolonged GLP-1R agonist intake [55, 56] is predicted to contribute to reduced ICP in obese idiopathic intracranial hypertension (IIH) patients, in whom weight loss represents a definite intervention to improve symptoms [57]
J., Campino, C., Germain, A., & Valenzuela, G
Lastly, we provide evidence that the mGIPR-Ab/GLP-1 peptideantibody conjugate accesses the CNS via the CVOs and activates neural pathways involved in regulating food intake and metabolism to induce weight loss
Your metabolism is not broken
Moreover, public health efforts that encourage the use of GLP-1 therapies, alongside growing awareness and access to branded semaglutide products, are further expanding the regional share of the industry